Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;6:117-31.
doi: 10.2147/OPTH.S27695. Epub 2012 Jan 12.

Topiramate and the Vision: A Systematic Review

Affiliations
Free PMC article

Topiramate and the Vision: A Systematic Review

Mohammad-Ali Abtahi et al. Clin Ophthalmol. .
Free PMC article

Abstract

Background and purpose: Topiramate (TPM) is a sulfa-derivative monosaccharide that is used mainly for treating epilepsy and preventing migraine. Within the gamut of side effects attributable to this drug, ophthalmologic manifestations are of crucial importance. In this study, for the first time, the aim was to provide a systematic literature review regarding this issue.

Methods: For the time period 1996-2011, a PubMed search was made for the studies concerning the adverse/beneficial effects of TPM on vision. Overall, 404 citations out of a total of 2756 TPM-related studies were examined for relevance.

Results: A total of 74 relevant studies were reviewed, 65 of which comprise small observational studies describing the ophthalmic side effects of TPM in 84 patients. Of these patients, 66 were affected by ciliochoroidal effusion syndrome as the cardinal ocular side effect of TPM (17 cases of myopic shift and 49 cases of angle closure glaucoma). A comprehensive statistical analysis is provided on these 66 subjects. Other rare side effects of TPM on the vision were also reviewed, including massive choroidal effusion, ocular inflammatory reactions, visual field defects, probable effects on retina, cornea, and sclera, and neuroophthalmologic complications. In addition, a framework is provided to classify these results.

Discussion: Due to the expanding spectrum of indications for the administration of TPM, neurologists and psychiatrists should be aware of its diverse ocular side effects. In conclusion, ocular complications following this drug should be taken seriously and be subjected to ophthalmic counseling.

Keywords: eye; ophthalmology; review; side effect; topiramate; vision.

Similar articles

See all similar articles

Cited by 24 articles

See all "Cited by" articles

References

    1. Angehagen M, Ronnback L, Hansson E, Ben-Menachem E. Topiramate reduces AMPA-induced Ca(2+) transients and inhibits GluR1 subunit phosphorylation in astrocytes from primary cultures. J Neurochem. 2005;94(4):1124–1130. - PubMed
    1. Panday VA, Rhee DJ. Review of sulfonamide-induced acute myopia and acute bilateral angle-closure glaucoma. Compr Ophthalmol Update. 2007;8(5):271–276. - PubMed
    1. Mirza NS, Alfirevic A, Jorgensen A, Marson AG, Pirmohamed M. Metabolic acidosis with topiramate and zonisamide: an assessment of its severity and predictors. Pharmacogenet Genomics. 2011;21(5):297–302. - PubMed
    1. United States Food and Drug Administration; Ortho-McNeil Pharmaceutical Inc. FDA approved labeling text. 2011. [Accessed August 27, 2011]. Available from: www.fda.gov/downloads/Drugs/DrugSafety/UCM152837.pdf.
    1. Christensen J, Hojskov CS, Dam M, Poulsen JH. Plasma concentration of topiramate correlates with cerebrospinal fluid concentration. Ther Drug Monit. 2001;23(5):529–535. - PubMed

LinkOut - more resources

Feedback